Cell line modeling for systems medicine in cancers (Review)

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 371-376

  Kim, Nayoung ^a   He, Ningning ^a   Yoon, Sukjoon ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Cancer cell line modeling; Drug sensitivity; NCI60; Systems medicine

Indexed keywords

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84894485405     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2202     Document Type: Article

References (34)

1. Kim N, He N, Kim C, et al: Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 131: 2456-2464, 2012.
2. Bussey KJ, Chin K, Lababidi S, et al: Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5: 853-867, 2006.
3. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607, 2012.
4. Park ES, Rabinovsky R, Carey M, et al: Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9: 257-267, 2010.
5. Lamb J: The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54-60, 2007.
6. Shoemaker RH, Monks A, Alley MC, et al: Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 276: 265-286, 1988.
7. Greshock J, Bachman KE, Degenhardt YY, et al: Molecular target class is predictive of in vitro response profile. Cancer Res 70: 3677-3686, 2010.
8. Bignell GR, Huang J, Greshock J, et al: High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 14: 287-295, 2004.
9. Zhao X, Weir BA, LaFramboise T, et al: Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570, 2005.
10. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950, 2011.
11. Weir BA, Woo MS, Getz G, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898, 2007.
12. Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758-764, 2007.
13. Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122, 2005.
14. 2+ signaling in selenium resistance. PLoS One 5: e12601, 2010.
15. Rantala JK, Edgren H, Lehtinen L, et al: Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia 12: 877-888, 2010.
16. Cheung HW, Cowley GS, Weir BA, et al: Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108: 12372-12377, 2011.
17. Abaan OD, Polley EC, Davis SR, et al: The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 73: 4372-4382, 2013.
18. Scherf U, Ross DT, Waltham M, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
19. Ross DT, Scherf U, Eisen MB, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235, 2000.
20. Dan S, Tsunoda T, Kitahara O, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147, 2002.
21. Spurrier B, Ramalingam S and Nishizuka S: Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3: 1796-1808, 2008.
22. Zubrod CG: Origins and development of chemotherapy research at the National Cancer Institute. Cancer Treat Rep 68: 9-19, 1984.
23. Paull KD, Shoemaker RH, Hodes L, et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989.
24. Deeken JF, Robey RW, Shukla S, et al: Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol 76: 946-956, 2009.
25. McDermott U, Sharma SV, Dowell L, et al: Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104: 19936-19941, 2007.
26. Karaman MW, Herrgard S, Treiber DK, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132, 2008.
27. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575, 2012.
28. He N, Wang X, Kim N, Lim JS and Yoon S: 3D shape-based analysis of cell line-specific compound response in cancers. J Mol Graph Model 43: 41-46, 2013.
29. Ma Q and Lu AY: Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63: 437-459, 2011.
30. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49, 2013.
31. Zeeberg BR, Kohn KW, Kahn A, et al: Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples. PLoS One 7: e40062, 2012.
32. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103, 2012.
33. Corcoran RB, Cheng KA, Hata AN, et al: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23: 121-128, 2013.
34. Lu Y, Muller M, Smith D, et al: Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30: 4567-4577, 2011.